Floatz logo

TACROLIMUS

Neuroepithelial Tumor

Montefiore Medical CenterSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Neuroepithelial Tumor cohort.

Asset / SponsorPhaseRating
Pembrolizumab
DNAtrix, Inc.
Phase 2B
TASADENOTUREV
DNAtrix, Inc.
Phase 2B
FILGRASTIM
St. Jude Children's Research Hospital
Phase 1CCC
Interleukin-12
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2CCC
Sonidegib
St. Jude Children's Research Hospital
Phase 1CC

View all 15 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →